Exelixis

Yahoo Finance • 3 months ago

Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

– Cabozantinib continues to demonstrate a significant improvement in progression-free survival versus placebo in patients with advanced neuroendocrine tumors, including across key subgroups – – Findings were the basis for the supplemental... Full story

Yahoo Finance • 4 months ago

Is Caligan Partners Bullish on Exelixis Inc (EXEL) Right Now?

We recently compiled a list of the Top 10 Holdings of Caligan Partners.In this article, we are going to take a look at where Exelixis Inc (NASDAQ:EXEL) stands against Caligan Partners' other top holdings. Founded in 2017, Caligan Partners... Full story

Yahoo Finance • 9 months ago

30 Biggest Biotechnology Companies in the World

In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the eve... Full story

Yahoo Finance • 10 months ago

4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

Putting your money to work on Wall Street hasn't been for the faint of heart since this decade began. Since the start of 2020, all three major stock indexes have traded off bear and bull markets in successive years, with the growth-driven... Full story

Yahoo Finance • 10 months ago

Jim Simons Increases Stake in Exelixis Inc

Overview of Jim Simons (Trades, Portfolio)'s Recent Portfolio Addition Warning! GuruFocus has detected 2 Warning Signs with EXEL. Renaissance Technologies, led by Jim Simons (Trades, Portfolio), has recently bolstered its investment in E... Full story

Yahoo Finance • 10 months ago

4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

Over multidecade periods, Wall Street has proved unstoppable. But over shorter time lines, the stock market's most prominent indexes have often been volatile and unpredictable -- perhaps none more so than the growth-fueled Nasdaq Composite... Full story

Yahoo Finance • 11 months ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif., February 01, 2024--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the... Full story

Yahoo Finance • 11 months ago

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

– Cabozantinib in combination with atezolizumab reduced the risk of disease progression or death by 35% in patients with metastatic castration-resistant prostate cancer – – Findings to be presented during an oral presentation at ASCO GU 2... Full story

Yahoo Finance • 11 months ago

Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – ALAMEDA, Calif., January 23, 2024--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2023 financial results will... Full story

Yahoo Finance • 11 months ago

European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets

ALAMEDA, Calif., January 18, 2024--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced it has successfully defended European Patent number EP2593090 (c-MET Modulator Pharmaceutical Compositions) against three opponents, STADA Ar... Full story

Yahoo Finance • 12 months ago

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

– Cabozantinib franchise achieves approximately $1.630 billion in preliminary U.S. net product revenues for fiscal year 2023 – – Fiscal year 2024 net product revenues guidance of $1,650 million - $1,750 million; 2024 R&D expense guidance... Full story

Yahoo Finance • 12 months ago

Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024

– Presentation to be webcast on www.exelixis.com – ALAMEDA, Calif., January 02, 2024--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, wi... Full story

Yahoo Finance • last year

11 Stocks Insiders and Billionaires Are Crazy About

In this article, we will take a detailed look at the11 Stocks Insiders and Billionaires Are Crazy About. For a quick overview of such stocks, read our article 5 Stocks Insiders and Billionaires Are Crazy About. In his famous book titled O... Full story

Yahoo Finance • last year

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – ALAMEDA, Calif. & HAYWARD, Calif., December 04, 2023--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Arcus Biosciences (NYSE: RCUS) today announce... Full story

Yahoo Finance • last year

Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023

– Presentation to be webcast on www.exelixis.com– ALAMEDA, Calif., November 21, 2023--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Piper Sandler 35th Ann... Full story

Yahoo Finance • last year

14 Best Cancer Stocks To Buy Now

In this article, we discuss 14 best cancer stocks to buy. If you want to skip our detailed discussion on the oncology industry, head directly to 5 Best Cancer Stocks To Buy Now. The global oncology landscape continues to evolve, with ongo... Full story

Yahoo Finance • last year

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel hormonal therapy in patients with metastatic castration-resistant p... Full story

Yahoo Finance • 2 years ago

3 No-Brainer Stocks to Buy With $200 Right Now

For instance, the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite, all plunged into a bear market in 2022 after rocketing to new highs in the previous year. For patient investors, it means corrections and bear markets represent... Full story

Yahoo Finance • 2 years ago

Farallon Capital Urges Exelixis Shareholders to Support Change by Electing Its Three Highly Qualified Director Candidates

Files Definitive Proxy Materials and Sends Letter to Exelixis Shareholders Encourages Shareholders to Show that the Status Quo Cannot Continue by Voting to Elect All Three of Farallon’s Independent Nominees on the WHITE Proxy Card Visit... Full story

Yahoo Finance • 2 years ago

These Stocks Moved the Most Today: C3.ai, Western Alliance, Albemarle, Tesla, and More

C3.ai fell sharply for a second day after a short seller alleges accounting issues at the artificial intelligence software company, and Western Alliance tumbled after issuing a business update without providing an exact deposit balance. C... Full story